Lupin gets USFDA approval for generic psoriasis drug
New Delhi: Drug major Lupin said it has received USFDA's approval to market Clobetasol Propionate spray, used for treating plaque psoriasis, in the American market.
Lupin's product is a generic version of Galderma Laboratories LP's Clobex, which is indicated for the treatment of moderate to severe plaque psoriasis.
As per sales data, the spray had annual sales of around USD 30.5 million in the US.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd